Invention Grant
- Patent Title: Multi-indication mRNA cancer immunotherapy
-
Application No.: US15114943Application Date: 2016-05-19
-
Publication No.: US09636388B2Publication Date: 2017-05-02
- Inventor: Michael J. P. Lawman , Patricia D. Lawman , Meghan Gentilini , Vijay Ramiya , Marina Victor Abdelmaseeh Bastawrous
- Applicant: MORPHOGENESIS, INC.
- Applicant Address: US FL Tampa
- Assignee: MORPHOGENESIS, INC.
- Current Assignee: MORPHOGENESIS, INC.
- Current Assignee Address: US FL Tampa
- Agency: Saliwanchik, Lloyd & Eisenschenk
- International Application: PCT/US2016/033235 WO 20160519
- International Announcement: WO2016/187407 WO 20161124
- Main IPC: A61K31/70
- IPC: A61K31/70 ; A61K48/00 ; C07H21/04 ; A61K39/00 ; A61K45/06 ; A01K67/00

Abstract:
Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
Public/Granted literature
- US20170042993A1 MULTI-INDICATION MRNA CANCER IMMUNOTHERAPY Public/Granted day:2017-02-16
Information query